Table 5.
Competing risk model results for extubation (alive)
| Variable | Multivariable subdistribution hazard ratio (95% confidence interval)1 |
|---|---|
|
| |
| Age (per 10 unit increase) | 0.92 (0.81–1.05) |
| MELD-Na (per unit increase) | 0.97 (0.95–0.98) |
| History of Decompensated Cirrhosis (HE, Ascites, OR Variceal Bleed) | 1.42 (0.90–2.23) |
| Indication (Referent: Procedure) | |
| AMS/HE | 0.34 (0.22–0.52) |
| Respiratory Failure/Cardiovascular Instability | 0.33 (0.23–0.47) |
| Rifaximin in the 24 h prior to intubation (Yes) | 0.48 (0.33–0.71) |
| Rifaximin in first 24 h post-intubation (Yes) | 1.74 (1.21–2.50) |
| Lactulose Enema received prior to intubation (yes) | 1.26 (0.70 –2.27) |
| Lactulose Enema received post-intubation (yes) | 1.13 (0.73–1.76) |
| Lactulose PO2 in the 24 h prior to intubation (per 10 g dose increase) | 1.03 (0.99–1.07) |
| Lactulose PO2 received in first 24 h post-intubation (per 10 g dose increase) | 1.03 (0.99–1.06) |
1
Statistically significant results are in bold
2
Oral administration